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The aim of the project was to assemble two optimum solid lipid nanoparticle (SLN)
formulations for oral delivery of loperamide (LPM) to treat different types of diarrhea,
and to evaluate their release profiles in vitro and pharmacokinetic properties in vivo. In
this work, glyceryl trimyristate (Dynasan 114) nanoparticles containing the drug LPM
and sodium cholate as a stabilizer were prepared using a modified solvent evaporation
technique. Two LPM-loaded SLNs, namely LPM-SLN-1 (LPM-SLN with a high ratio
rate of lipid to drug) and LPM-SLN-2 (LPM-SLN with a low ratio rate of lipid to drug),
were prepared by the solvent evaporation method. A change in the lipid concentration
affects the characteristics of LPM-SLNs. The average sizes of the LPM-SLNs were
303 ± 18 nm and 519 ± 36 nm, separately, as analyzed by dynamic light scattering.
The LPM-SLNs were found to be round with a smooth surface, as observed using a
transmission electron microscope and a scanning electron microscope. The average
encapsulation efficiencies were 87 ± 3.78% w/w and 84 ± 5.17%, accordingly. In the
in vitro release experiments, LPM-SLNs showed a continuous release profile of LPM
without any burst release. The oral bioavailability of LPM-SLNs was analyzed using
Wistar rats. The relative bioavailabilities of LPM-SLNs were 227 and 153%, respectively,
as compared that of the LPM tablet. There was no difference in the Tmax between LPM-
SLN-2 and the LPM tablet. In conclusion, LPM-SLN-1 significantly improved the oral
bioavailability of LPM, while LPM-SLN-2 having the same swift action as the LPM tablet.
These results demonstrate the potential of LPM-SLNs in the oral delivery of LPM to treat
different types of diarrhea.
Keywords: poorly water-soluble drugs, solid lipid nanoparticles, sustained release, oral delivery formulation,
loperamide
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INTRODUCTION
Loperamide (LPM) is an orally administered antidiarrheal agent
indicated for the short-term treatment of acute and chronic
diarrhea in adults (Natalja et al., 2013). LPM is available in
a range of orally administered formulations, including tablets,
capsules, a combination chewable tablet, and an orodispersible
formulation (Trottet et al., 2004). However, LPM has limitations
in oral administration owing to its extreme bitter taste. Moreover,
LPM is a poorly water-soluble drug. Its slow dissolution rate
in the intestinal tract and its significant first-pass effect largely
restrict its clinical use (Trottet et al., 2004). To overcome these
challenges, Ueda and Kreuter (1997) had successfully loaded LPM
into Poly(L-lactide) nanoparticles to increase its solubility and
to improve its release profile in vitro (Ueda and Kreuter, 1997).
However, there are few reports on the formulation of LPM solid
lipid nanoparticles (SLNs), which could be a possible way to
overcome the limitations in the oral absorption of LPM.
Delivering drugs to their site of therapeutic action is one
of the main challenges faced by the pharmaceutical industry
(Parveen et al., 2012). This can be due to a range of factors,
such as the chemical properties of the drug, biological processes,
or patient factors, such as age or disease state (Mehnert and
Mader, 2001; Perrie et al., 2012). An exciting area of research
aiming to overcome some of these limitations is nanotechnology.
In particular, the pharmaceutical industry is keenly interested in
research into nanoencapsulation, which involves the formation
of drug-loaded particles with a diameter of 1−1000 nm (Pinto
Reis et al., 2006). This technology has many potential benefits,
including improved drug bioavailability and solubility, increased
plasma half-life, selective targeting, reduced toxicity, increased
stability, and provision for controlled drug release (Budhian et al.,
2007; Luo et al., 2011; Danhier et al., 2012; Parveen et al., 2012;
Wang et al., 2012a,b).
One important area of nanoencapsulation is the development
SLNs. SLNs encompass a broad range of colloidal systems,
which can include micro emulsions, liposomes, and polymeric
nanoparticles (Schwarz and Mehnert, 1997; Mehnert and Mader,
2001; Luo et al., 2011). The nanoparticles consist of a matrix
made up of a solid lipid shell (solid at room and body
temperature; Luo et al., 2011; Fathi et al., 2012) that is stabilized
by emulsifiers and contains a loaded drug cargo (Luo et al.,
2011; Parveen et al., 2012; Mo et al., 2015). SLNs combine the
advantages of various colloidal carrier systems (Harde et al.,
2011; Zhang et al., 2012) by incorporating the advantages of the
solid matrix of polymeric nanoparticles with the advantages of
micro emulsions and liposomes in having low biological toxicity
(Casadei et al., 2006; Harde et al., 2011). Glyceryl trimyristate
(Dynasan 114) is a triglyceride that has been the component
of several novel SLN formulations (Thava Seelan and Leggat,
2003; Leggat, 2005). Dynasan 114 SLNs have demonstrated the
ability to be degraded within 60−120 min in the simulated
gastrointestinal tract, when combined with a suitable surfactant
such as sodium cholate (Thava Seelan and Leggat, 2003; Leggat,
2005). It has also been shown to be non-toxic for human use
and is officially recognized as a pharmaceutical excipient. It is
used as a lubricant in tablets and as a seeding/crystallization
agent to improve the solidification process in suppositories,
vaginal ovules, and cosmetic sticks. The combined low toxicity
and degradative properties suggest a potential for drug-loaded
Dynasan 114 SLN to be used in orodispersible formulations
(Thava Seelan and Leggat, 2003; Leggat, 2005; Wilder-Smith,
2008). Nanoencapsulation of a drug in Dynasan 114 SLN can
potentially mask the unpleasant taste of the drug, eliminate
the gritty sensation within the mouth offered by micron-sized
particles (<3 µm), while allowing for the rapid release of
the incorporated drug upon Dynasan 114 degradation in the
gastrointestinal tract.
The aim for the study is to assemble stable LPM-loaded
SLNs and further explore the possibility of using these novel
formulations to cure different kinds of diarrhea. LPM-loaded
Dynasan 114 SLNs were prepared using the solvent evaporation
method, with modifications (Mehnert and Mader, 2001; Wang
et al., 2012b). The formulation was evaluated for its mean
diameter (MD), polydispersity index (PDI), zeta potential (ZP),
and drug loading (DL) and entrapment efficiency (EE). The
effects of freeze drying on the stability of the formulation
were also investigated. Then, the LPM release from SLN was
investigated in vitro, and its oral bioavailability was analyzed
in vivo.
MATERIALS AND METHODS
Materials
Chemicals used for the synthesis of nanoparticles were
loperamide (>99%, Sigma Aldrich, St Louis, MO, USA), sodium
cholate hydrate (>99%, Sigma), glyceryl trimyristate (Dynasan
114; >99%, Sigma), and dichloromethane (>99.5%, Sigma).
Purified water (MilliQ, Millipore, USA) was used throughout and
all other chemicals were of analytical grade. All experiments were
conducted at room temperature (25◦C). Loperamide tablets were
purchased from Xian Janssen Pharmaceutical Ltd, Xi’an, China.
Preparation of Loperamide-Loaded Solid
Lipid Nanoparticles
The loperamide-loaded SLNs (LPM-SLNs) were prepared by
a solvent evaporation technique, with modifications (Mehnert
and Mader, 2001; Wang et al., 2012b). The non-aqueous phase
consisted of 250 mg of Dynasan 114 and 5 mg or 15 mg
of loperamide (50:1 or 16.7:1 w/w) dissolved in 1.5 ml of
dichloromethane. The aqueous phase consisted of 50 mg of
sodium cholate (added to give a weight ratio of 1:5 to Dynasan
114) dissolved in 30 ml of purified water. The non-aqueous
phase was added dropwise into the aqueous phase under rapid
stirring at 500 rpm for homogenous dispersion (Magnetic
Stirrer CS76083V, Industrial Equipment and Control Pty LTD,
Australia). After 1 min of stirring, the homogenous dispersion
was sonicated (Vibra cell Model VCX130, Sonics and Materials
Inc, USA) at 80% amplitude for 5 min. The dispersion was
transferred to a rotary evaporator in a 50-ml round bottom
flask and the organic solvent was allowed to evaporate over
30 min at 80 rpm at 25◦C (Rotavapor R-210, Buchi Labortechnik,
Switzerland). The dispersion was collected and analyzed, or
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freeze dried for further analysis. The composition of each of the
different formulations is summarized in Table 1 and referenced
by identification name.
Mean Diameter, Polydispersity Index,
and Zeta Potential of SLN Samples
The particle size and PDI were determined by dynamic light
scattering (DLS; Zetasizer Nano ZS, Malvern Instruments Ltd,
Worcestershire, UK). Particle size, PDI, and ZP measurements
of the SLN dispersion were performed immediately after
manufacturing, and again after the dispersion had been freeze
dried and reconstituted in purified water. In all cases, the
dispersion was measured immediately after it was allowed to
equilibrate for 2 min in the equipment.
Transmission Electron Microscope (TEM)
and Scanning Electron Microscope
(SEM) Analysis
The morphology of LPM-SLN formulations was studied using
transmission electron microscopy (JEM-1200EX, JEOL; Mo et al.,
2016). One drop of LPM-SLNs was diluted 50-fold with pure
water before placing onto a 400-mesh carbon film, copper grid,
and then negatively stained with 1% phosphotungstic acid. The
sample was air-dried before TEM inspection (Mo et al., 2016).
The surface morphology of LPM-SLN formulations was
observed by scanning electron microscopy (1555VP FESEM,
Zeiss, Jena, Germany; Mo et al., 2015). Before observation, the
lyophilized samples were fixed on a double adhesive carbon tape,
which was stuck on aluminum stubs and then coated with gold
under an argon atmosphere. The samples were visualized by SEM
with an accelerating voltage of 8–20 kV (Mo et al., 2015).
HPLC Analysis of LPM
The mass analysis of LPM was performed by reverse-phase
HPLC. The HPLC system consisted of a model LC-10AT pump
(Shimadzu, Kyoto, Japan) and a model SPD-10A UV detector
(Shimadzu; Mo et al., 2011). The stationery phase was Diamonsil
C18 (200 × 4.6 mm, 5 µm; Dikma, USA). The injection volume
was 20 µl; a mixture of 0.1 mol/l ammonium carbonate and
acetonitrile (90:10, v/v) was used as a mobile phase with a flow
rate of 1.0 ml/min. The UV detection wavelength was 264 nm;
the column temperature was 30◦C.
Entrapment Efficiency and Drug Loading
The EE of LPM-SLNs was calculated by determining the amount
of free drug obtained after ultrafiltration (Mo et al., 2015). One
milliliter LPM-loaded SLN colloidal solution was ultrafiltered
for 10 min at 4000 rpm. The ultrafiltrate containing the
TABLE 1 | Composition of loperamide loaded solid lipid nanoparticles.
ID Name Loperamide
HCl (mg)
Sodium
cholate (mg)
Dynasan 114
(mg)
Ratio
LPM-SLN-1 5 50 250 1: 10: 50
LPM-SLN-2 15 50 250 1: 3.3: 16.7
unencapsulated drug was analyzed using HPLC. The total LPM
in LPM-SLNs was determined by breaking up the LPM-SLNs
as described previously, with minor modifications (Mo et al.,
2014b). Aliquots of 1 ml LPM-SLN dispersions were vortexed
with 2.5 ml of methanol for 5 min, followed by filtration through
0.45 µm membrane filters. The filtrate was transferred into glass
autosampler vials and a 20-µl aliquot sample was injected into
HPLC, as mentioned above, for analysis. The DL was the weight
of the encapsulated drug divided by the weight of the lipid (w/w).
The EE and the DL were calculated by the following equations:
EE (%) = WTotal−WFree
WTotal
× 100%
Drug loading (%) = WTotal−WFree
WLipid
× 100%
Freeze Drying and Reconstitution
LPM-SLN dispersions were frozen at −40◦C for 24 h (Medical
freezer, Model MDF135, Sanyo Ltd, Japan). The frozen samples
were then freeze dried (VirTis Freezemobile 35 EL, SP Scientific)
over 48 h to yield a powdery sample. To determine whether the
freeze-dried powder could be reconstituted into SLNs, 30 mg of
the powder was resuspended in 3 ml of purified water to yield
the same concentration of SLNs (1% w/v) as was present in the
initial dispersion prior to freeze drying. To aid the dispersion of
the SLN, the resuspended sample was either vortexed for 5 min
at 2400 rpm (Heidolph Reax Top, John Morris Scientific Pty Ltd,
Germany) or sonicated for 2 min at 80% amplitude (Vibra cell
Model VCX130).
In vitro Release Studies
The release rates of LPM from LPM-SLN-1, LPM-SLN-2, and
LPM tablets were investigated using dialysis bags at pH 1.2 and
pH 6.8. LPM-SLN-1, LPM-SLN-2, and LPM tablets equivalent
to 10 mg of LPM were placed into a dialysis bag (Spectrum
Laboratories, Inc., Rancho Dominguez, CA, USA; molecular
weight cut off, 3500 Da) containing 1000 ml PBS (pH 1.2 or 6.8)
with 1% Tween 80, at 37.5◦C. At different time points, the release
medium in which the dialysis bag was immersed was sampled
(5 ml) for analysis by the above mentioned HPLC method.
In vivo Pharmacokinetics
All animal experiments were carried out following the Principles
of Laboratory Animal Care (People’s Republic of China; Mo et al.,
2014a), and the protocols for the animal studies were approved
by the Department of Laboratory Animal Research at Guilin
Medical University (License No. YXLL-2015-039). Male Wistar
rats (7−8 weeks old) weighing 200–250 g were obtained from
Animal experimental center of Guilin Medical University and
housed at a temperature of 25 ± 2◦C. The rats were divided
randomly into three groups containing six animals each and
fasted overnight before the experiment, but had free access to
water. Fasting minimizes the influence of food on intestinal
absorption of LPM and its formulations.
The rats were weighed before the administration of LPM-SLNs
(5 mg/ml) or an equivalent dose of the LPM tablet by gavage at a
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dose of 5 µl/g of body weight. Blood samples were collected as
previously reported (Mo et al., 2014a). Briefly, 0.5 ml blood was
sampled from each animal, via the suborbital vein using capillary
tube method at 0, 0.17, 0.33, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, and
16 h after administration. All blood samples were immediately
centrifuged at 5000 rpm for 10 min to separate the plasma. The
plasma obtained was stored at−80◦C until analysis.
The concentrations of LPM in rat plasma were determined by
HPLC as mentioned above. Samples were prepared as following:
0.4 ml plasma was mixed with 0.2 ml 0.3 M NaOH and vigorously
vortexed for 1 min. Then, 2 ml of ethyl acetate was added and the
mixture was vortexed for 5 min. The organic layers were collected
after centrifugation at 5000 rpm for 5 min, and evaporated to
dryness. The residue was dissolved in 0.2 ml of the mobile phase
by vortexing for 5 min and 20 µl was injected into the HPLC.
The major pharmacokinetic parameters were determined
by DAS 2.0 (Mathematical Pharmacology Professional
Committee of China, Shanghai, China). The values of maximum
concentration (Cmax) and time of maximum concentration
(Tmax) were read directly from the concentration–time curves.
Plasma concentration vs. time data were fitted into a two-
compartment model to obtain estimates of the area under
the plasma concentration–time curve during the period of
observation (AUC0−t). The relative bioavailability of the SLN
formulations was calculated by the following formula:
Fr(%) = AUCTDR
AUCRDT
× 100%
where, Fr was the relative bioavailability, AUC was the area
under the plasma concentration, D was the dose administrated,
T was the test formulation (oral administration of LPM-loaded
SLNs formulations), R was the reference formulation (oral
administration of LPM tablet; Mo et al., 2014a).
Statistical Analysis
All batches were produced in triplicates except when mentioned
otherwise. All values are expressed as mean ± SD. Statistical
analysis of the mean values between batches was performed using
the Student’s t-test (Excel 2010, Microsoft, Redmond, WA, USA).
The differences were considered significant when p< 0.05.
RESULTS AND DISCUSSION
Physiochemical Characteristics of
LPM-SLNs
The DLS measurements for LPM-SLN-1 showed a mean size of
303 ± 18 nm, with a PDI of 0.19 ± 0.01. A histogram of the size
distribution showed a peak at 342 nm and a normal distribution
with size range of 68−1484 nm (Figure 1A). ZP measurements
suggested that LPM-SLN-1 possessed a high negative surface
charge of−47.33± 4.29 mV.
The DLS measurements for LPM-SLN-2 showed a mean
size of 519 ± 36 nm, with a PDI of 0.18 ± 0.01 and ZP of
−54.63 ± 8.12 mV. The size distribution histogram showed a
slightly broader continuous distribution with a peak at 458 nm
and a slight positive skew between 122 and 1484 nm (Figure 1B).
The particle sizes of three batches of LPM-SLN-1 and LPM-SLN-
2 were 296.65 nm, 323.75 nm, and 289.6 nm; and 526.84 nm,
550.69 nm, and 479.47 nm, respectively. The MD of the two
formulations was significantly different (p = 0.00295). However,
LPM-SLN-2 did not show a statistically significant difference in
ZP (p> 0.05) when compared to LPM-SLN-1. Interestingly, there
was no increase in the PDI (p> 0.05), confirming that an increase
in the drug load in LPM-SLN-2 did not widen the nanoparticle
size distribution, as compared to LPM-SLN-1.
Morphology of LPM-SLN Formulations
Figures 1C,D show the images of surface morphology of LPM-
SLNs. The results showed that the particles were spherical with a
narrow size distribution, and had smooth surfaces. No crystals of
the drug or aggregation of nanoparticles was found in the sample.
The morphology of LPM-SLNs determined by TEM is shown
in Figures 1E,F. The TEM study showed that the particles had
almost round and uniform shape and did not stick to each other.
HPLC for Determination of Loperamide
after the Production of Loperamide SLN
A calibration curve of absorbance versus concentration was
plotted using standard solutions of loperamide HCl using HPLC.
As shown in Figure 2, a linear regression analysis of the data
produced a line with an R2 value of 0.9979 and the equation:y =
42.864x− 356.58. The retention time for LPM was 8.7 min.
Drug Loading and Entrapment Efficiency
Drug loading and entrapment efficiency were calculated using
the equations described in the Methods section. A DL of
1.57± 0.31% w/w and 4.25± 0.38% w/w and an EE of 87± 3.78%
w/w and 84 ± 5.17% w/w were obtained for LPM-SLN-1 and
LPM-SLN-2, respectively.
Freeze Drying
The LPM-SLN samples were freeze dried to determine whether
the SLNs were amendable to freeze drying. The freeze-dried
samples were reconstituted in purified water by either vortexing
or sonication. As shown in Figure 3, vortexing resulted in the
reconstituted samples exhibiting a large MD of 483 ± 135 nm
for LPM-SLN-1 and 853 ± 289 nm for LPM-SLN-2; a PDI of
0.44 ± 0.08 and a ZP of −29.6 ± 0.53 mV for LPM-SLN-1; a
PDI of 0.42 ± 0.11 and a ZP of −25.1 ± 2.47 mV for LPM-SLN-
2. Conversely, sonication resulted in the samples having an MD
of 313 ± 28 nm for LPM-SLN-1 and 531 ± 36 nm for LPM-
SLN-2; a PDI of 0.13 ± 0.08 and a ZP of -49.6 ± 0.42 mV for
LPM-SLN-1; a PDI of 0.22 ± 0.07 and a ZP of −38.1 ± 3.27 mV
for LPM-SLN-2. The samples reconstituted via vortexing had
significantly larger MD, PDI, and smaller ZP values, as compared
to reconstitution via sonication (p< 0.05). The sonicated samples
had similar MD and PDI values as the freshly prepared samples.
These experiments suggest that freeze-dried LPM-SLNs were
fairly well reconstituted by sonication. Lyophilization is a possible
way to preserve LPM-SLNs.
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FIGURE 1 | Loperamide-loaded Dynasan 114 solid lipid nanoparticles [LPM (loperamide)-SLN (solid lipid nanoparticle)]. (A) Z-average size of
LPM-SLN-1, (B) Z-average size of LPM-SLN-2, (C) SEM image of LPM-SLN-1, (D) SEM (scanning electron microscope) image of LPM-SLN-2, (E) TEM
(transmission electron microscope) image of LPM-SLN-1, (F) TEM image of LPM-SLN-2; scale bar 200 nm.
FIGURE 2 | (A) Typical chromatograms for loperamide HCl. (B) Calibration curve obtained for loperamide HCl in the range of 6−100 µg/ml.
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FIGURE 3 | Particle sizes of LPM-SLN formulations after lyophilization and reconstitution by vortexing or sonication. ∗p < 0.05.
FIGURE 4 | In vitro release profile of LPM from different vehicles at (A) pH 1.2 and (B) pH 6.8. Each value represents the mean ± S.D. (n = 3).
In vitro Release Study
The LPM release profiles at different pHs are shown in Figure 4.
The release profiles of LPM-SLNs at pH 1.2 and pH 6.8 showed
no burst releases of LPM at the beginning in both media, which
verifies that there was little drug attached to the surface of
SLNs. A continuous release profile was observed at pH 6.8.
The accumulated dissolution of LPM from SLNs in PBS (pH
6.8) over 48 h was about 80%, whereas, it was less than 20%
from commercial tablets (Mo et al., 2014a). However, LPM
commercial tablets released more drug (up to 80%) at pH 1.2 in
4 h because of the weakly alkaline nature of LPM, while it was
less than 20% in LPM-SLNs. These results indicate that LPM was
encapsulated in SLNs and was protected from the strong acidic
environment within the stomach. After the LPM-SLNs reach the
small intestine, the intact LPM would be released from the LPM-
SLNs. The results suggested that the majority of the LPM in SLNs
could be taken up by intestinal cells. The release profiles of LPM-
SLN-1 and 2 were similar at pH 1.2, but different at pH 6.8. The
release of the drug from LPM-SLN-1 was slower than that from
LPM-SLN-2.
The release profiles of the drug from LPM-SLN-1 and 2 in
PBS (pH 6.8) were fitted to a Ritger–Peppas kinetics model
using Origin 8.5 and the following equations were obtained: ln
R = 0.8071 ln t − 0.2452 (r = 0.9896) for LPM-SLN-1 and
ln R = 0.7549 ln t − 0.3147 (r = 0.9934) for LPM-SLN-2.
Based on the fitting result using the Ritger–Peppas model (ln
R = k ln t + C; Mo et al., 2011), the values of k were 0.8121
and 0.6954, respectively (0.45 < k < 0.85), which indicated that
LPM release from SLNs was due to drug diffusion and lipid
matrix corrosion. (Zhuang et al., 2010) The k value was close to
0.85, which indicated that matrix corrosion is the leading cause
of drug release and most of the drug is located inside SLNs.
A minor amount of the drug within the shell could diffuse into
the medium.
In vivo Pharmacokinetics
Figure 5 shows the plasma concentration-time profiles of
LPM after oral administration of different LPM formulations
to male Wistar rats. The corresponding PK parameters are
given in Table 2. The Tmax was 0.33 h and the Cmax
Frontiers in Pharmacology | www.frontiersin.org 6 September 2016 | Volume 7 | Article 332
fphar-07-00332 September 17, 2016 Time: 15:32 # 7
Wei et al. Loperamide Loaded SLN for Oral
FIGURE 5 | Mean plasma LPM concentration-time curves obtained
after oral administration in Wistar rats. Each value represents the
mean ± S.D. (n = 6).
was 461.72 ± 49.15 ng/ml when the LPM tablet was orally
administrated. The Tmax of LPM-SLN-1 (2 h) was about one and
half hour later than that of the LPM tablet. The difference between
Tmax values of LPM-SLN-1 and the LPM tablet demonstrated
that the absorption modes of the two formulations were different.
The LPM in the tablet dissolved in the intestinal tract and
was absorbed directly into the systemic circulation. Therefore,
the plasma concentration of LPM quickly reached the plateau
in 0.33 h. However, the drug from LPM-SLN-1 was slowly
released into the gastrointestinal tract, which was verified by the
in vitro release experiments. Interestingly, the Tmax values were
not significantly different between LPM tablet and LPM-SLN-
2, which may be attributed to the bigger size of LPM-SLN-2,
leading to an easy diffusion of the drug from the lipid matrix.
The Cmax values of LPM-SLN-1 and 2 were 731.87± 43.89 ng/ml
and 638.98 ± 50.06 ng/ml, respectively, which were substantially
higher than that of the LPM tablet (461.72 ± 49.15 ng/ml).
At all except the first three time points, the LPM plasma
TABLE 2 | Pharmacokinetic parameters determined from the plasma
concentration-time profiles of Wistar rats after oral administration with
LPM (loperamide)-SLN (solid lipid nanoparticle)-1, LPM-SLN-2, and LPM
tablet equivalent LPM dose of 5 mg/kg body weight. (n = 6; Mean ± SD).
LPM tablet LPM-SLN-1 LPM-SLN-2
parameters Mean ± SD Mean ± SD Mean ± SD
AUC(0− t) (ng/ml∗h) 421.45 ± 23.12 955.35 ± 54.40∗ 643.43 ± 12.14∗
Cmax (ng/ml) 461.72 ± 49.15 731.87 ± 43.89∗ 638.98 ± 50.06
Tmax (h) 0.33 ± 0 2 ± 0∗ 0.5 ± 0
Vd (L/kg) 155.00 ± 33.62 57.02 ± 6.78∗ 75.95 ± 5.30
CL (L/h/kg) 122.19 ± 7.37 58.39 ± 2.73∗ 75.64 ± 2.43
t1/2 (h) 1.28 ± 0.45 6.73 ± 8.64∗ 3.57 ± 1.38∗
∗p < 0.05, comparison with LPM tablet.
concentrations in rats treated with LPM-SLNs were significantly
higher than those treated with the LPM tablet. (Mo et al.,
2014a) Sixteen hours after oral administration of LPM-SLNs-
1 and 2, the LPM plasma concentrations were 20.47 ng/ml
and 9.47 ng/ml, respectively; although, the drug concentration
was 11.47 ng/ml 8 h after treatment with the LPM tablet. The
AUC0→t after oral administration of LPM–SLN-1 and 2 were
955.35± 54.40 ng/ml/h and 643.43± 12.14 ng/ml/h, respectively,
which were nearly 2.3- and 1.5-fold higher than that of the LPM
tablet (421.45± 23.12 ng/ml/h).
Since the equal amount of LPM in SLN formulations and
tablet was used for in vivo experiment, relative bioavailability of
SLN formulations is determined by dividing AUC0−t of LPM
SLN formulations by AUC0−t of LPM tablet. Thus, Frs of LPM-
SLN-1 and LPM-SLN-2 were 227 and 152%, correspondingly,
which meaned more LPM in SLNs crossed intestinal barrier into
systemic circle, compared to LPM tablet.
The results suggest that the systemic absorption of LPM was
drastically improved by incorporation into SLNs as compared to
tablets (Zhuang et al., 2010). Higher Cmax and sustained release
profile of LPM-SLN-1 would result in better treatment of chronic
diarrhea. While LPM-SLN-2 had similar Tmax as the LPM tablet,
its profile makes it more suitable for treatment of acute diarrhea.
Overall, the LPM-SLNs indicate an encouraging potential of
increasing the oral bioavailability of water-insoluble drugs along
with an ability to mask unpleasant taste.
DISCUSSION
The main factors contributing to the low bioavailability of LPM
are its poor water-solubility, significant first pass effect in the liver,
and the obstacle of the intestinal epithelial cell. Hence, we used
SLNs to overcome these problems and propose the mechanism
by which the effects are obtained.
First of all, SLNs are composed of different lipids whose
structures are similar to the fat found in foods. The lipids could
stimulate bile secretion to the small intestinal and the LPM
released from SLNs was mixed with bile salts to form micelles
which would improve its solubility (Zhuang et al., 2010).
Secondly, as LPM is a weakly alkaline molecule, it forms salt
at a low pH (1.2), which subsequently increases its solubility.
After oral administration of LPM tablets, the drug would quickly
dissolve in the gastric fluid (Zhuang et al., 2010); and upon
moving to the intestinal tract, the drastic increase in the pH would
cause the precipitation of the drug (Zhuang et al., 2010). This
transition would cause its adherence to the wall of the intestinal
tract. The sustained release characteristics of SLNs could achieve
a longer retention time in vivo.
Finally, sodium cholate was used as a surfactant in this study,
which may increase the LPM absorption. Sodium cholate is one
of the bile salts, and might improve the intestinal epithelial
permeability by interrupting the cell membrane (Zhuang
et al., 2010). Sodium cholate can attach to the p-glycoprotein
irreversibly and inhibit the p-glycoprotein eﬄux pump, which
would increase the attachment of LPM to the intestinal mucosa
(Mo et al., 2014a).
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Solid lipid nanoparticles were designed in the 1990s
as an alternative to the existing drug delivery systems,
such as emulsions, liposomes, and polymeric nanoparticles
(Doktorovova et al., 2014). SLNs are formulated either
with physiological lipids or with lipids and are have a
generally regarded as safe (GRAS) status. SLNs can protect
sensitive drug molecules from the external surroundings
and even have controlled release profiles. However, common
disadvantages of SLNs are often related with their low drug
loading capacity, unpredictable gelation tendency, and so on.
Drug loading capacity depends highly on the crystallinity
of the lipids. In the current study, glyceryl trimyristate,
which was used as the lipid, is an ester with the chemical
formula C45H86O6. It is a long chain saturated fat. However,
the encapsulated loperamide is a complex compound with
three benzene rings. Thus, the high crystallinity of glyceryl
trimyristate may lead to a rather low loperamide loading
capacity.
Many attempts have been made to address the issue of
low loading capacity. Nanostructured lipid carriers (NLC) were
initially introduced (Muller et al., 2000). In these formulations,
lipids of highly ordered crystalline structures are mixed with
different lipids of amorphous structures, to obtain structured
matrices that accommodate more drugs (Bondi and Craparo,
2010). The drug loading capacity of SLNs was increased by
combining natural solid lipids with lipids of different chain
lengths (Parhi and Suresh, 2012). It was noted that lipids
could form matrices of scrambled structures composed of
mixed crystals and mixtures of crystals, which enhanced drug
incorporation as compared to a single lipid (Weber et al.,
2014).
Wassim Abdelwahed (2015) prepared LPM-loaded SLNs
by high shear homogenization method. A mixture of
beeswax, carnauba wax, and egg lecithin was used as
lipids to encapsulate LPM into the nanoparticles. This
resultant drug-loaded SLN was found to have the optimal
particle size for brain targeting. More importantly, the
researcher revealed that using 5% monosaccharide glucose
solution as cryoprotectant could better help LPM loaded-
SLNs withstand the freezing dry stress (Abdelwahed, 2015).
On the basis of these findings, in future experiments,
different lipids such as natural lipid theobroma oil and/or
synthetic lipid tri-palmitic acid could be mixed with glyceryl
trimyristate so as to increase the drug loading of LPM, and
cryoprotectants would be tested for better reconstitution
profiles.
The water solubility of loperamide is very limited (about
0.00086 mg/mL at 20◦C). Tween 80 (Polysorbate 80,
polyoxyethylene sorbitan monooleate) is a hydrophilic non-
ionic surfactant widely used in emulsification and dispersion
of substances in medicinal and food products (Strickley, 2004).
Hence, in our dissolution experiment, 1% tween 80 was used
for increasing the LPM solubility in the release medium to meet
“sink condition.”
LD50 of LPM for oral administration in rats is 185 mg/kg.
Oral doses (2.5–40 mg/kg) several times the antidiarrheal dose,
unlike diphenoxylate, do not produce narcotic-like actions (Heel
et al., 1978). In our preliminary experiments to screen the optimal
loperamide dose for rats, four doses of loperamide (2.5, 10, 25,
and 40 mg/kg) were tested. In case of the former two doses
(2.5, 10 mg/kg), the drug plasma concentration was too low to
be measured by HPLC, whereas the drug plasma concentrations
after the latter two doses (25, 40 mg/kg) were well above lower
limit of quantification. In order to avoid severe adverse effects on
experimental animals, the lower dose of 25 mg/kg was chosen as
optimal dosage for in vivo experiments.
CONCLUSION
In this project, LPM-SLNs for oral delivery were successfully
formulated by a solvent evaporation technique. The resultant
LPM-SLNs formulations had relevant and homogeneous particle
size with high encapsulation efficiency. It could be preserved
and easily restored after lyophilization. In vitro experiments
revealed a sustained release of the drug by LPM-SLNs, with
little burst-release effect at pH 6.8. In vivo pharmacokinetic
experiments indicated that the relative bioavailabilities of the
LPM-SLN formulations were 227 and 153% higher than that
of the LPM tablet in Wistar rats after oral administration. The
SLNs could increase the gastrointestinal absorption of LPM.
The nanostructured lipid vehicle provides a promising way to
improve the oral bioavailability of water-insoluble drugs. The
two different formulae were designed for different clinical usages.
Based on these results, further investigations would be carried out
to establish the exact mechanism underlying increased LPM oral
absorption by this formulation.
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